<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tizanidine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tizanidine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tizanidine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11098" href="/d/html/11098.html" rel="external">see "Tizanidine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="112669" href="/d/html/112669.html" rel="external">see "Tizanidine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F228405"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zanaflex</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868431"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-TiZANidine;</li>
<li>GEN-TiZANidine;</li>
<li>MINT-Tizanidine;</li>
<li>PAL-TiZANidine [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F228439"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Alpha<sub>2</sub>-Adrenergic Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F228409"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Patients more sensitive to sedating and other CNS adverse effects (eg, older adults, patients with organ impairment) may better tolerate a reduced dose, less frequent administration, and/or more gradual titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chou.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chou.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Switching between capsules and tablets may alter effect as these preparations are not bioequivalent when administered with food.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="064c5452-fb88-4f4e-9599-745fd4b6f2cc">Muscle spasm and/or musculoskeletal pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Muscle spasm and/or </b>
<b>musculoskeletal</b>
<b>pain (adjunctive therapy) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For skeletal muscle spasm and/or pain (eg, low back pain, neck pain) with muscle spasm, usually in combination with nonsteroidal anti-inflammatory drugs and/or acetaminophen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28192790','lexi-content-ref-19421791','lexi-content-ref-12973146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28192790','lexi-content-ref-19421791','lexi-content-ref-12973146'])">Ref</a></span>). In general, muscle relaxants should be used temporarily (eg, for a few days or intermittently for a few days when needed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2 to 4 mg every 8 to 12 hours as needed and/or at bedtime; some may benefit by scheduling doses initially. May increase based on response and tolerability up to a maximum dose of 24 mg/day (eg, 4 to 8 mg every 8 hours as needed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chou.2022','lexi-content-ref-Knight.2022','lexi-content-ref-19421791','lexi-content-ref-12973146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chou.2022','lexi-content-ref-Knight.2022','lexi-content-ref-19421791','lexi-content-ref-12973146'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b9696f64-895f-4d97-bbb7-9feeb1ed243d">Spasticity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spasticity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For muscle spasticity due to neurologic injury or disease (eg, multiple sclerosis, stroke, spinal cord injury, traumatic brain injury, amyotrophic lateral sclerosis [ALS]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22336799','lexi-content-ref-15276195','lexi-content-ref-27711973','lexi-content-ref-25096594','lexi-content-ref-27207462','lexi-content-ref-14583932','lexi-content-ref-16565680']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22336799','lexi-content-ref-15276195','lexi-content-ref-27711973','lexi-content-ref-25096594','lexi-content-ref-27207462','lexi-content-ref-14583932','lexi-content-ref-16565680'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2 mg once daily usually at bedtime; may increase based on response and tolerability in increments of 2 to 4 mg per day (with a minimum of 1 to 4 days between dose increases) up to a maximum dose of 36 mg/day in 3 or 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11486114','lexi-content-ref-25096594','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11486114','lexi-content-ref-25096594','lexi-content-ref-Manu.1'])">Ref</a></span>). In the treatment of spasticity associated with stroke (eg, hemiplegic shoulder pain), some experts initiate therapy with 2 mg every 8 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Creutzfeldt.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Creutzfeldt.2022'])">Ref</a></span>). In the treatment of spasticity associated with ALS, some experts limit dose to 24 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Galvez.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Galvez.2022'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Discontinuation of therapy:</i></b> Gradually taper total daily dose by 2 to 4 mg to reduce the risk of rebound symptoms (eg, hypertension, tachycardia, hypertonia), especially in patients receiving high doses (eg, ≥16 mg/day) for long periods (eg, ≥9 weeks) or in patients who have been receiving concomitant opioids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29467587','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29467587','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990834"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: Oral: </b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥25 to &lt;60 mL/minute: Initial: No specific dosage adjustment recommended (has not been studied); however, tizanidine is primarily renally eliminated; use with caution. Start at the low end of the dosing range and monitor for side effects with increased doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;25 mL/minute: Initial: 2 mg once daily; may increase based on response and tolerability by 2 mg per day (with a minimum of 1 to 4 days between dose increases). Use with caution; clearance reduced &gt;50%. If higher doses are necessary, consider increasing the dose instead of increasing dosing frequency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9074844','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9074844','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzable (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 2 mg once daily; use with caution, as clearance in patients with severe kidney dysfunction is reduced &gt;50%. Slowly increase based on tolerability and response in 2 mg increments. If higher doses are necessary, consider increasing the dose instead of increasing dosing frequency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15828911','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15828911','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b>Unlikely to be significantly dialyzable (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 2 mg once daily; use with caution, as clearance in patients with severe kidney dysfunction is reduced &gt;50%. Slowly increase based on tolerability and response in 2 mg increments. If higher doses are necessary, consider increasing the dose instead of increasing dosing frequency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Unlikely to be significantly dialyzable (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 2 mg once daily; use with caution, as clearance is reduced in patients with kidney dysfunction. Slowly increase based on tolerability and response in 2 mg increments. If higher doses are necessary, consider increasing the dose instead of increasing dosing frequency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Unlikely to be significantly dialyzable (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 2 mg once daily; use with caution, as clearance is reduced in patients with kidney dysfunction. Slowly increase based on tolerability and response in 2 mg increments. If higher doses are necessary, consider increasing the dose instead of increasing dosing frequency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988056"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Avoid use in hepatic impairment; if used, reduce dose during initial dose titration. If higher doses are necessary, increase dose instead of increasing dosing frequency. Monitor aminotransferases.</p></div>
<div class="block doe drugH1Div" id="F228410"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Use with caution; clearance is decreased. Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F51196693"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="112669" href="/d/html/112669.html" rel="external">see "Tizanidine: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>The tablet and capsule dosage forms are not bioequivalent when administered with food.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8232ceae-b998-49cf-b821-9c327d889779">Spasticity associated with cerebral palsy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Spasticity associated with cerebral palsy: </b>Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19073853','lexi-content-ref-25999301','lexi-content-ref-Haque.2020','lexi-content-ref-Oleszek.2020','lexi-content-ref-16272661']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19073853','lexi-content-ref-25999301','lexi-content-ref-Haque.2020','lexi-content-ref-Oleszek.2020','lexi-content-ref-16272661'])">Ref</a></span>): Dosing based on small open-label trials and clinical experience.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial dose:</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to &lt;10 years: Oral: 1 mg at bedtime; titrate as needed.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥10 years and Adolescents: Oral: 2 mg at bedtime; titrate as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">Titration and maintenance dose: Children ≥2 years and Adolescents: Oral: Titrate initial dose upward to reported effective range of 0.3 to 0.5 mg/kg/day in 3 to 4 divided doses; maximum daily dose: 24 mg/<b>day</b>. <b>Note:</b> In adults, when discontinuation of therapy is necessary, doses are gradually tapered by 2 to 4 mg daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51220252"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific dosage recommendations; use with caution (tizanidine is primarily renally eliminated); based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51220253"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific dosage recommendations; based on experience in adult patients, dosing adjustment suggested; use with caution.</p></div>
<div class="block arsc drugH1Div" id="F56344066"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Asymptomatic, reversible <b>increased liver enzymes</b> (most notably alanine aminotransferase [ALT]) and severe <b>hepatotoxicity</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8938559','lexi-content-ref-28323749','lexi-content-ref-7970010','lexi-content-ref-11318882','lexi-content-ref-9074844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8938559','lexi-content-ref-28323749','lexi-content-ref-7970010','lexi-content-ref-11318882','lexi-content-ref-9074844'])">Ref</a></span>). Resolution in patients with clinically significant increases in liver enzymes occurs upon discontinuation. In patients with severe hepatotoxicity, recovery has occurred within 1 to 2 months of discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8938559','lexi-content-ref-11318882']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8938559','lexi-content-ref-11318882'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; unknown, may be due to immunologic reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8938559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8938559'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; reported 2 to 4 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8938559','lexi-content-ref-11318882','lexi-content-ref-9074844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8938559','lexi-content-ref-11318882','lexi-content-ref-9074844'])">Ref</a></span>). Upon rechallenge, increases in ALT have been reported within 6 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8938559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8938559'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Underlying hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18671474']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18671474'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Reversible <b>hypotension </b>has been demonstrated in 7% to 12% of patients receiving tizanidine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25456780','lexi-content-ref-15383642','lexi-content-ref-18320182','lexi-content-ref-15462150','lexi-content-ref-9074844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25456780','lexi-content-ref-15383642','lexi-content-ref-18320182','lexi-content-ref-15462150','lexi-content-ref-9074844'])">Ref</a></span>). <b>Orthostatic hypotension</b> has also been reported ((<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31535247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31535247'])">Ref</a></span>). Hypotension may lead to <b>asthenia</b>, <b>dizziness</b>, <b>syncope</b>, or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25456780','lexi-content-ref-11486114','lexi-content-ref-15383642','lexi-content-ref-7970013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25456780','lexi-content-ref-11486114','lexi-content-ref-15383642','lexi-content-ref-7970013'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, alpha-2 adrenergic agonist) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30223305','lexi-content-ref-15462150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30223305','lexi-content-ref-15462150'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; occurs within 30 minutes to 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25456780','lexi-content-ref-15383642','lexi-content-ref-18320182','lexi-content-ref-15462150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25456780','lexi-content-ref-15383642','lexi-content-ref-18320182','lexi-content-ref-15462150'])">Ref</a></span>). <b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses and rapid titration</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent CYP1A2 inhibitors (eg, ciprofloxacin is associated with a 10-fold and fluvoxamine with a 33-fold increase in tizanidine concentrations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15592331']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15592331'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications that cause hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11198499','lexi-content-ref-15383642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11198499','lexi-content-ref-15383642'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Underlying hepatic impairment (Child-Pugh score ≥7) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18320182']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18320182'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sedation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Non–life-threatening, reversible <b>sedated state</b> occurs in 24% to 50% of patients receiving a standard dose (≤36 mg/day) of tizanidine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15276195','lexi-content-ref-11486114','lexi-content-ref-15505149','lexi-content-ref-7970010','lexi-content-ref-9074844','lexi-content-ref-7970013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15276195','lexi-content-ref-11486114','lexi-content-ref-15505149','lexi-content-ref-7970010','lexi-content-ref-9074844','lexi-content-ref-7970013'])">Ref</a></span>). Sedation leading to coma has occurred with tizanidine overdose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15462150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15462150'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, alpha-2 adrenergic agonist) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11486114','lexi-content-ref-27207462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11486114','lexi-content-ref-27207462'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; may occur within 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15260084','lexi-content-ref-15462150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15260084','lexi-content-ref-15462150'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of alcohol</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent CYP1A2 inhibitors (eg, ciprofloxacin is associated with a 10-fold and fluvoxamine with a 33-fold increase in tizanidine concentrations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15592331']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15592331'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent CNS depressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15260084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15260084'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Underlying kidney impairment</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Abrupt discontinuation of tizanidine has led to potentially life-threatening <b>withdrawal syndrome</b>, including possible dysthermia, hallucinations, hypertension, nausea, tremor, and tachycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21353141','lexi-content-ref-29467587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21353141','lexi-content-ref-29467587'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related (ie, hypersecretion of catecholamines following cessation of alpha-2 agonism) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29467587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29467587'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; occurs within 12 to 24 hours of cessation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29467587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29467587'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High doses (≥16 mg daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29467587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29467587'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged use (≥9 weeks)</p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21353141','lexi-content-ref-29467587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21353141','lexi-content-ref-29467587'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent cessation of other CNS depressants (eg, baclofen, benzodiazepines, opioids) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21353141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21353141'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F228385"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adolescents and adults.</p>
<p style="text-indent:0em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Xerostomia (49%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (41%)<span class="lexi-table-link-container"> (<a aria-label="Asthenia table link" class="lexi-table-link" data-table-id="lexi-content-asthenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-asthenia')">table 1</a>)</span><span class="table-link" style="display:none;">Asthenia</span>, dizziness (16%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 2</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drowsiness (48%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 3</a>)</span><span class="table-link" style="display:none;">Drowsiness</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Asthenia" frame="border" id="lexi-content-asthenia" rules="all">
<caption style="text-align:center;">
<b>Tizanidine: Adverse Reaction: Asthenia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tizanidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tizanidine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">41%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">264</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">261</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Tizanidine: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tizanidine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tizanidine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">261</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Tizanidine: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tizanidine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tizanidine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">48%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">261</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (4%), vomiting (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary frequency (3%), urinary tract infection (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (most notably increased serum alanine aminotransferase) (6%)<span class="lexi-table-link-container"> (<a aria-label="Increased Liver Enzymes table link" class="lexi-table-link" data-table-id="lexi-content-increased-liver-enzymes" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-liver-enzymes')">table 4</a>)</span><span class="table-link" style="display:none;">Increased Liver Enzymes</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Liver Enzymes" frame="border" id="lexi-content-increased-liver-enzymes" rules="all">
<caption style="text-align:center;">
<b>Tizanidine: Adverse Reaction: Increased Liver Enzymes</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tizanidine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tizanidine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Oral tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">264</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">261</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Delusion (≤3%), nervousness (3%), speech disturbance (3%), visual hallucination (≤3%) (Khan 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia (≤3%), blurred vision (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (3%), pharyngitis (3%), rhinitis (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (Cortes 2014, Masood 2018), hypotension (Kao 2004, Momo 2008), orthostatic hypotension (Farrell 2020), syncope, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exfoliative dermatitis, skin rash, Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (de Graaf 1996), hepatotoxicity (de Graaf 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression, paresthesia, sedated state (Gelber 2001), seizure, tremor, withdrawal syndrome (Suárez-Lledó 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia</p></div>
<div class="block coi drugH1Div" id="F228396"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concomitant therapy with potent CYP1A2 inhibitors (eg, ciprofloxacin, fluvoxamine).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to tizanidine or any component of the formulation; patients requiring spasticity to maintain function (eg, maintenance of upright posture, balance in locomotion).</p></div>
<div class="block war drugH1Div" id="F228382"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use not recommended in patients with hepatic impairment; potential for effects likely due to extensive hepatic metabolism of tizanidine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Clearance decreased significantly in patients with severe impairment (CrCl &lt;25 mL/minute); dose reductions recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Use with caution; clearance decreased fourfold in older adults (≥65 years of age); may increase risk of adverse effects and/or duration of effects. Older adults with severe renal impairment (CrCl &lt;25 mL/minute) may have clearance reduced by &gt;50% compared to healthy older adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Food: Food alters absorption profile relative to administration under fasting conditions. In addition, bioequivalence between capsules and tablets is altered by food; capsules and tablets are bioequivalent under fasting conditions, but not under nonfasting conditions.</p></div>
<div class="block foc drugH1Div" id="F228392"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zanaflex: 2 mg, 4 mg, 6 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 4 mg, 6 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zanaflex: 4 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 4 mg</p></div>
<div class="block geq drugH1Div" id="F228378"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F228397"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (tiZANidine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $1.22 - $2.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $3.43 - $3.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg (per each): $5.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Zanaflex Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $4.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $5.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg (per each): $8.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (tiZANidine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $1.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $1.46 - $1.47</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Zanaflex Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $4.09</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868432"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 4 mg</p></div>
<div class="block adm drugH1Div" id="F518407"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Capsules may be opened and contents sprinkled on food; however, extent of absorption is increased up to 20% relative to administration of the capsule under fasted conditions.</p></div>
<div class="block admp drugH1Div" id="F52613938"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be taken with or without food but consistent administration with regard to meals is recommended (due to impact on absorption). Capsules may be opened and contents sprinkled on food (eg, applesauce); however, extent of absorption is increased up to 20% relative to administration of the intact capsule under fasted conditions.</p></div>
<div class="block use drugH1Div" id="F228393"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Spasticity:</b> Management of spasticity; reserve treatment with tizanidine for daily activities and times when relief of spasticity is most important.</p></div>
<div class="block off-label drugH1Div" id="F53841867"><span class="drugH1">Use: Off-Label: Adult</span><p>Muscle spasm and/or musculoskeletal pain (adjunctive therapy)</p></div>
<div class="block mst drugH1Div" id="F228445"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">TiZANidine may be confused with nizatidine, tiaGABine.</p>
<p style="text-indent:-2em;margin-left:4em;">Zanaflex may be confused with Xiaflex.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Zanaflex capsules and Zanaflex tablets (or generic tizanidine tablets) are not interchangeable in the fed state.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F3015415"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F228387"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May increase the serum concentration of TiZANidine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): May increase the serum concentration of TiZANidine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inducers (Moderate): May decrease the serum concentration of TiZANidine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Moderate): May increase the serum concentration of TiZANidine. Management: If combined use cannot be avoided, initiate tizanidine in adults at 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Strong): May increase the serum concentration of TiZANidine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Weak): May increase the serum concentration of TiZANidine. Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elranatamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epcoritamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glofitamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If the combination cannot be avoided, monitor for decreased effects of alpha2-agonists if mirtazapine is initiated/dose increased, or increased effects if mirtazapine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mosunetuzumab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: May increase the serum concentration of CYP1A2 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the therapeutic effect of Alpha2-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talquetamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teclistamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of TiZANidine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding this combination. If used, monitor for decreased effects of the alpha2-agonist. Exercise great caution if discontinuing an alpha2-agonist in a patient receiving a TCA.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F228404"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">The tablet and capsule dosage forms are not bioequivalent when administered with food. Food increases both the time to peak concentration and the extent of absorption for both the tablet and capsule. However, maximal concentrations of tizanidine achieved when administered with food were increased by 30% for the tablet, but decreased by 20% for the capsule. Under fed conditions, the capsule is approximately 80% bioavailable relative to the tablet. Management: Administer with or without food, but keep consistent.</p></div>
<div class="block rep_considerations drugH1Div" id="F55363084"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Oral contraceptives may decrease the clearance of tizanidine; concomitant use of oral contraception is not recommended by the manufacturer. Consult drug interactions database for details related to management of patients taking tizanidine with CYP1A2 inhibitors (weak).</p></div>
<div class="block pri drugH1Div" id="F13206218"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Information related to use of tizanidine in pregnancy is limited (Eleftheriou 2014).</p></div>
<div class="block brc drugH1Div" id="F13206219"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if tizanidine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F4591382"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Administration with food compared to administration in the fasting state results in clinically-significant differences in absorption and other pharmacokinetic parameters. Patients should be consistent and should not switch administration of the tablets or the capsules between the fasting and nonfasting state. In addition, switching between the capsules and the tablets in the fed state will also result in significant differences. Opening capsule contents to sprinkle on applesauce compared to swallowing intact capsules whole will also result in significant absorption differences. Patients should be consistent with regards to administration.</p></div>
<div class="block mop drugH1Div" id="F228390"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor LFTs at baseline and during use (including 1 month after maximum dose achieved) or if hepatic injury suspected; BP (including prior to dose increase); renal function; mental alertness.</p></div>
<div class="block pha drugH1Div" id="F228381"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">An alpha<sub>2</sub>-adrenergic agonist agent which decreases spasticity by increasing presynaptic inhibition; effects are greatest on polysynaptic pathways; overall effect is to reduce facilitation of spinal motor neurons.</p></div>
<div class="block phk drugH1Div" id="F228395"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Single dose (8 mg): Peak effect: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Single dose (8 mg): 3 to 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Tablets and capsules are bioequivalent under fasting conditions, but not under nonfasting conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets administered with food: Peak plasma concentration is increased by ~30%; time to peak increased by 25 minutes; extent of absorption increased by ~30%.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules administered with food: Peak plasma concentration decreased by 20%; time to peak increased by 2 to 3 hours; extent of absorption increased by ~10%.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules opened and sprinkled on applesauce are not bioequivalent to administration of intact capsules under fasting conditions. Peak plasma concentration and AUC are increased by 15% to 20%; time to peak decreased by 15 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: IV: 2.4 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~30%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via CYP1A2 to inactive metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~40% (extensive first-pass metabolism)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~2.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Fasting state: Capsule, tablet: 1 hour</p>
<p style="text-indent:-2em;margin-left:4em;">Fed state: Capsule: 3 to 4 hours, Tablet: 1.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (60%); feces (20%)</p></div>
<div class="block phksp drugH1Div" id="F51204279"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance is reduced more than 50% in elderly patients with renal function impairment (creatinine clearance &lt;25 mL/minute) compared with healthy subjects; this may lead to longer duration of clinical effects.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Extensively metabolized in the liver and significant effects are expected; use not recommended in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Younger subjects cleared drug 4 times faster than elderly subjects.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F228398"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Tizanidal</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Tizagelan | Tizanidin Actavis</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Relentus | Sirdalud | Tizadine | Tizalud</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Musant | Tizanidine</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de Tizanidina | Sirdalud</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Tizanidin Orion</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Carefufe | Chang bang | Kai lai tong</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Airflex | Alertadina | Cimbrar | Impoflex | Lamidon | Mio relax | Miorelax | Myos nor | Myos-nor | Relaxkov | Sirdalud | Tizanidina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Pirdan | Sirdalud</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Tizanidine Teva</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Caredalud | Epcidin | Myoldin | Rekan | Roysan | Sirdalud | Smr | Tizyl</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Tizagelan | Tizanidin Actavis | Tizanidin Alternova | Tizanidin Copyfarm | Tizanidin Orion | Tizanidin Teva</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Tizanidine | Tizanidine kent | Tizanidine niche | Zanaflex</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Tizanidin Altamedics</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Tizagelan</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Myores | Phardex | Sirdalud | Tizacom | Tizanidine | Zitanid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Tizaflex | Tizanidine niche | Zanaflex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Prinim t | Sirdalud | Tizadin | Tizan | Tizpa</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Navizan | Sirdalud | Tizagelan | Tizanidina</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Astonelin | Astonelin choseido | Dohfarche | Enchinin | Etanaldin | Gibonz | Gibonz mita | Herusenelin | Mekitack | Motonalin | Pelixal | Sevretin | Sevretin merck hoei | Telzanine | Ternelin | Terrelark | Tetorinen | Theorate | Tirolbit | Tizanelin | Tizanidine | Tizanin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Relezin | Sirdalud | Tizigesic</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Soften | Tizalead</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Tizanidine Teva</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Nadiamyr | Sirdalud | Sirdalud mr | Tizanidina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Tizanidine</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Relezin | Sirdalud | Tizanidine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Sirdalud retard | Tizanidin Teva | Zanaflex</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Tizanidine</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Ternelax</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Agile | Analar | Arcozid | Cibtaz | Delpoflex | Demzoflex | Dyzo | Efibac | Ezad | Ezidin | Fernor | Kadin | Lentil | Lintiz | Lozeden | Maxlax | Micnic | Movax | Mr x | Mudine | Muscaset | Musidin | Muslex | Mutin | Mylex | Myodine | Myotiz | Nazeden | Nyer | Ob terline | Redeem | Relaxamed | Relaxamed sr | Relaxit | Rexant | Ronelin | Seflex | Skelgesic | Skelwin | Sn skelax | Soneta | Spasfree | Spastiz | Strive | Tandolax | Tanin | Tanzic | Tanzoflex | Tenavax | Terlax | Ternelin | Tezany | Tezany fort | Tiflex | Tigesic | Timzi | Tinadine | Tinex | Tinize | Tizadin | Tizarex | Tizax | Tizaxidine | Tizenax | Tizgic | Tizilex | Tizirel | Tizodine | Tizpa | Tonsic | Trajin | Trans-Din | Turz | Unixidine | Xantix | Xinasia | Zadin | Zanaflex | Zandic | Zandin | Zaniflex | Zanita | Zantid | Zenile | Zid | Zinad | Zinlax | Zinzan | Zita</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Tizanidine Arrow | Tizanor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Tizanidine | Tizanidine HCL | Zanaflex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Tizanidina Teva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Tizaflex</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Relezin | Sirdalud</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Sirdalud mr | Tisalud | Tizanidin | Tizanidin Teva | Tizanidine | Tizanidine sz | Tizanil</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Relezin | Sirdalud | Tilax</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Tizanidin Teva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Tidar | Tizan | Tonolyte</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Devalud | Sirdalud</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Spaslax | Stidine | Tizalin | Tizan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Tizalud | Tizanidin ratiopharm</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Mioflex | Sirdalum | Tiflex | Tizafen</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Sirdalud | Tizanidina</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Colthimus | Novalud | Waruwari</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Sirdakud</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-APS.1">
<a name="APS.1"></a>American Pain Society (APS).<i> Principles of Analgesic Use</i>. 7th ed. Chicago, IL: American Pain Society; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22336799">
<a name="22336799"></a>Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. <i>Cochrane Database Syst Rev</i>. 2012;(2):CD004156. doi:10.1002/14651858.CD004156.pub4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/22336799/pubmed" id="22336799" target="_blank">22336799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2967780">
<a name="2967780"></a>Berry H, Hutchinson DR. A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain. <i>J Int Med Res</i>. 1988;16(2):75-82. doi:10.1177/030006058801600201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/2967780/pubmed" id="2967780" target="_blank">2967780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30223305">
<a name="30223305"></a>Chaugai S, Dickson AL, Shuey MM, et al. Co-prescription of strong CYP1A2 inhibitors and the risk of tizanidine-associated hypotension: a retrospective cohort study. <i>Clin Pharmacol Ther</i>. 2019;105(3):703-709. doi:10.1002/cpt.1233<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/30223305/pubmed" id="30223305" target="_blank">30223305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28192790">
<a name="28192790"></a>Chou R, Deyo R, Friedly J, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. <i>Ann Intern Med</i>. 2017;166(7):480-492. doi:10.7326/M16-2458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/28192790/pubmed" id="28192790" target="_blank">28192790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15276195">
<a name="15276195"></a>Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. <i>J Pain Symptom Manage</i>. 2004;28(2):140-175. doi:10.1016/j.jpainsymman.2004.05.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/15276195/pubmed" id="15276195" target="_blank">15276195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chou.2022">
<a name="Chou.2022"></a>Chou R. Subacute and chronic low back pain: nonpharmacologic and pharmacologic treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25456780">
<a name="25456780"></a>Cortes J, Hall B, Redden D. Profound symptomatic bradycardia requiring transvenous pacing after a single dose of tizanidine. <i>J Emerg Med</i>. 2015;48(4):458-460. doi:10.1016/j.jemermed.2014.10.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/25456780/pubmed" id="25456780" target="_blank">25456780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Creutzfeldt.2022">
<a name="Creutzfeldt.2022"></a>Creutzfeldt CJ. Neuropalliative care of stroke. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25999301">
<a name="25999301"></a>Dai AI, Aksoy SN, Demiryürek AT. Comparison of efficacy and side effects of oral baclofen versus tizanidine therapy with adjuvant botulinum toxin type A in children with cerebral palsy and spastic equinus foot deformity. <i>J Child Neurol</i>. 2016;31(2):184-189. doi:10.1177/0883073815587030.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/25999301/pubmed" id="25999301" target="_blank">25999301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19073853">
<a name="19073853"></a>Dai AI, Wasay M, Awan S. Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity. <i>J Child Neurol</i>. 2008;23(12):1464-1466. doi:10.1177/0883073808319074.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/19073853/pubmed" id="19073853" target="_blank">19073853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8938559">
<a name="8938559"></a>de Graaf EM, Oosterveld M, Tjabbes T, Stricker BH. A case of tizanidine-induced hepatic injury. <i>J Hepatol</i>. 1996;25(5):772-773. doi:10.1016/s0168-8278(96)80252-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/8938559/pubmed" id="8938559" target="_blank">8938559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24909848">
<a name="24909848"></a>Eleftheriou G, Butera R, Lorenzi F, et al. Tizanidine use in pregnancy. Abstracts from the 2nd International Joined OTIS - ENTIS Conference, September 18-21, 2014, Toronto, Canada. <i>Birth Defects Res A Clin Mol Teratol</i>. 2014;100(7):532. doi:10.1002/bdra.23258<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/24909848/pubmed" id="24909848" target="_blank">24909848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31535247">
<a name="31535247"></a>Farrell MC, Biaggioni I, Shibao CA. Neurogenic orthostatic hypotension induced by tizanidine. <i>Clin Auton Res</i>. 2020;30(2):173-175. doi:10.1007/s10286-019-00637-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/31535247/pubmed" id="31535247" target="_blank">31535247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Galvez.2022">
<a name="Galvez.2022"></a>Galvez-Jimenez N. Symptom-based management of amyotrophic lateral sclerosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11486114">
<a name="11486114"></a>Gelber DA, Good DC, Dromerick A, Sergay S, Richardson M. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. <i>Stroke</i>. 2001;32(8):1841-1846. doi:10.1161/01.str.32.8.1841<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/11486114/pubmed" id="11486114" target="_blank">11486114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28323749">
<a name="28323749"></a>Gill D, Allam F, Boyle J. Importance of medication reconciliation: tizanidine-induced hepatitis. <i>Am J Ther</i>. 2017 Sep/Oct;24(5):e623-e624. doi:10.1097/MJT.0000000000000497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/28323749/pubmed" id="28323749" target="_blank">28323749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15592331">
<a name="15592331"></a>Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. <i>Clin Pharmacol Ther</i>. 2004;76(6):598-606. doi:10.1016/j.clpt.2004.08.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/15592331/pubmed" id="15592331" target="_blank">15592331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Haque.2020">
<a name="Haque.2020"></a>Haque N, Saha N, Ahmed T, Debnath B, Hossain Mollah A, Rahman E. Comparison of baclofen and tizanidine in reducing spasticity in cerebral palsy: a randomized control trial. <i>Open J Pediatr</i>. 2020;10:617-625. doi:10.4236/ojped.2020.104063</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6451461">
<a name="6451461"></a>Hennies OL. A new skeletal muscle relaxant (DS 103-282) compared to diazepam in the treatment of muscle spasm of local origin. <i>J Int Med Res</i>. 1981;9(1):62-68. doi:10.1177/030006058100900111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/6451461/pubmed" id="6451461" target="_blank">6451461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15260084">
<a name="15260084"></a>Imanaga K, Wajima Z, Inoue T, Ogawa R. Effect of oral tizanidine on local-anesthetic infiltration pain during epidural catheterization. <i>J Nippon Med Sch</i>. 2004;71(2):105-110. doi:10.1272/jnms.71.105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/15260084/pubmed" id="15260084" target="_blank">15260084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11198499">
<a name="11198499"></a>Johnson TR, Tobias JD. Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension. <i>J Child Neurol</i>. 2000;15(12):818-819. doi:10.1177/088307380001501211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/11198499/pubmed" id="11198499" target="_blank">11198499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15383642">
<a name="15383642"></a>Kao CD, Chang JB, Chen JT, Wu ZA, Shan DE, Liao KK. Hypotension due to interaction between lisinopril and tizanidine. <i>Ann Pharmacother</i>. 2004;38(11):1840-1843. doi:10.1345/aph.1E161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/15383642/pubmed" id="15383642" target="_blank">15383642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21353141">
<a name="21353141"></a>Karol DE, Muzyk AJ, Preud'homme XA. A case of delirium, motor disturbances, and autonomic dysfunction due to baclofen and tizanidine withdrawal: a review of the literature. <i>Gen Hosp Psychiatry</i>. 2011;33(1):84.e1-e2. doi:10.1016/j.genhosppsych.2010.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/21353141/pubmed" id="21353141" target="_blank">21353141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khan.2012">
<a name="Khan.2012"></a>Khan R, Nicolas J, and Sachde H. Tizanidine for the management of chronic migraines. Abstract. <i>The Journal of Pain</i>. 2012;S71.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15828911">
<a name="15828911"></a>Kitabata Y, Orita H, Kamimura M, et al. Symptomatic bradycardia probably due to tizanidine hydrochloride in a chronic hemodialysis patient. <i>Ther Apher Dial</i>. 2005;9(1):74-77. doi:10.1111/j.1774-9987.2005.00206.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/15828911/pubmed" id="15828911" target="_blank">15828911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Knight.2022">
<a name="Knight.2022"></a>Knight CL, Deyo RA, Staiger TO, Wipf JE. Treatment of acute low back pain. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27711973">
<a name="27711973"></a>Lindsay C, Kouzouna A, Simcox C, Pandyan AD. Pharmacological interventions other than botulinum toxin for spasticity after stroke. <i>Cochrane Database Syst Rev</i>. 2016;10:CD010362. doi:10.1002/14651858.CD010362.pub2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/27711973/pubmed" id="27711973" target="_blank">27711973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18671474">
<a name="18671474"></a>Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. <i>Expert Opin Pharmacother</i>. 2008;9(12):2209-2215. doi:10.1517/14656566.9.12.2209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/18671474/pubmed" id="18671474" target="_blank">18671474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28177941">
<a name="28177941"></a>Masood U, Kahlon A, Mousa O. Clinically significant bradycardia from tizanidine. <i>Am J Ther</i>. 2018;25(3):e385-e386. doi:10.1097/MJT.0000000000000554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/28177941/pubmed" id="28177941" target="_blank">28177941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18320182">
<a name="18320182"></a>Momo K, Homma M, Abei M, Hyodo I, Kohda Y. Tizanidine-induced hypotension in patients with liver cirrhosis. <i>Eur J Clin Pharmacol</i>. 2008;64(6):647-648. doi:10.1007/s00228-008-0469-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/18320182/pubmed" id="18320182" target="_blank">18320182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15505149">
<a name="15505149"></a>Montané E, Vallano A, Laporte JR. Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. <i>Neurology</i>. 2004;63(8):1357-1363. doi:10.1212/01.wnl.0000141863.52691.44<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/15505149/pubmed" id="15505149" target="_blank">15505149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25096594">
<a name="25096594"></a>Nair KP, Marsden J. The management of spasticity in adults. <i>BMJ</i>. 2014;349:g4737. doi:10.1136/bmj.g4737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/25096594/pubmed" id="25096594" target="_blank">25096594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7970010">
<a name="7970010"></a>Nance PW, Bugaresti J, Shellenberger K, Sheremata W, Martinez-Arizala A. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. <i>Neurology</i>. 1994;44(11 Suppl 9):S44-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/7970010/pubmed" id="7970010" target="_blank">7970010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oleszek.2020">
<a name="Oleszek.2020"></a>Oleszek JL, Davidson LT. Spasticity. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap 730.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27207462">
<a name="27207462"></a>Otero-Romero S, Sastre-Garriga J, Comi G, et al. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Mult Scler</i>. 2016;22(11):1386-1396. doi:10.1177/1352458516643600.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/27207462/pubmed" id="27207462" target="_blank">27207462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19421791">
<a name="19421791"></a>Pareek A, Chandurkar N, Chandanwale AS, Ambade R, Gupta A, Bartakke G. Aceclofenac-tizanidine in the treatment of acute low back pain: a double-blind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone. <i>Eur Spine J</i>. 2009;18(12):1836-1842. doi:10.1007/s00586-009-1019-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/19421791/pubmed" id="19421791" target="_blank">19421791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16272661">
<a name="16272661"></a>Patel DR, Soyode O. Pharmacologic interventions for reducing spasticity in cerebral palsy. <i>Indian J Pediatr</i>. 2005;72(10):869-872.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/16272661/pubmed" id="16272661" target="_blank">16272661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20101040">
<a name="20101040"></a>Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society, Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. <i>Neurology</i>. 2010;74(4):336-343. doi:10.1212/WNL.0b013e3181cbcd2f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/20101040/pubmed" id="20101040" target="_blank">20101040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11318882">
<a name="11318882"></a>Saper JR, Winner PK, Lake AE 3rd. An open-label dose-titration study of the efficacy and tolerability of tizanidine hydrochloride tablets in the prophylaxis of chronic daily headache. <i>Headache</i>. 2001;41(4):357-368. doi:10.1046/j.1526-4610.2001.111006357.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/11318882/pubmed" id="11318882" target="_blank">11318882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14583932">
<a name="14583932"></a>Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. <i>Cochrane Database Syst Rev</i>. 2003;(4):CD001332. doi:10.1002/14651858.CD001332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/14583932/pubmed" id="14583932" target="_blank">14583932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sirdalud.1998">
<a name="Sirdalud.1998"></a>Sirdalud Ternelin Asia-Pacific Study Group. Efficacy and gastroprotective effects of tizanidine plus diclofenac versus placebo plus diclofenac in patients with painful muscle spasms. <i>Curr Ther Res</i>. 1998;59(1):13-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/Sirdalud.1998/pubmed" id="Sirdalud.1998" target="_blank">Sirdalud.1998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15462150">
<a name="15462150"></a>Spiller HA, Bosse GM, Adamson LA. Retrospective review of tizanidine (zanaflex) overdose. <i>J Toxicol Clin Toxicol</i>. 2004;42(5):593-596. doi:10.1081/clt-200026978<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/15462150/pubmed" id="15462150" target="_blank">15462150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29467587">
<a name="29467587"></a>Suárez-Lledó A, Padullés A, Lozano T, Cobo-Sacristán S, Colls M, Jódar R. Management of tizanidine withdrawal syndrome: a case report. <i>Clin Med Insights Case Rep</i>. 2018;11:1179547618758022. doi:10.1177/1179547618758022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/29467587/pubmed" id="29467587" target="_blank">29467587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16565680">
<a name="16565680"></a>Taricco M, Pagliacci MC, Telaro E, Adone R. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review. <i>Eura Medicophys</i>. 2006;42(1):5-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/16565680/pubmed" id="16565680" target="_blank">16565680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Par.1">
<a name="Par.1"></a>Tizanidine [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; May 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mint.1">
<a name="Mint.1"></a>Tizanidine [product monograph]. Mississauga, Ontario, Canada: Mint Pharmaceuticals; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12973146">
<a name="12973146"></a>van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM; Cochrane Back Review Group. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the Cochrane Collaboration. <i>Spine (Phila Pa 1976)</i>. 2003;28(17):1978-1992. doi:10.1097/01.BRS.0000090503.38830.AD.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/12973146/pubmed" id="12973146" target="_blank">12973146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9074844">
<a name="9074844"></a>Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. <i>Drugs</i>. 1997;53(3):435-452. doi:10.2165/00003495-199753030-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/9074844/pubmed" id="9074844" target="_blank">9074844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7970013">
<a name="7970013"></a>Wallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. <i>Neurology</i>. 1994;44(11 Suppl 9):S60-S68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tizanidine-drug-information/abstract-text/7970013/pubmed" id="7970013" target="_blank">7970013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zanaflex.1">
<a name="Zanaflex.1"></a>Zanaflex (tizanidine) [prescribing information]. Zug, Switzerland: Covis Pharma; December 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9999 Version 613.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
